ProCE Banner Activity

Newly Diagnosed and Recurrent Glioblastoma: Overview of Current Status and Treatment

Slideset Download

Download these expert-selected slides on the diagnosis and treatment of glioblastomas.

Released: April 05, 2022

Share

Faculty

Andrew B. Lassman

Andrew B. Lassman, MD

Chief, Neuro-Oncology Division
Department of Neurology
Columbia University Irving Medical Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Karyopharm Therapeutics Inc.

Sumitomo Dainippon Pharma ONC

Faculty Disclosure

Primary Author

Andrew B. Lassman, MD

Chief, Neuro-Oncology Division
Department of Neurology
Columbia University Irving Medical Center
New York, New York

Andrew B. Lassman, MD, has disclosed that he has received research support paid to his institution from AbbVie, Aeterna Zenaris, Bayer, BeiGene, Bristol-Myers Squibb, Chimerix, Corden, DelMar, Genentech/Roche, Kadmon, Karyopharm, Kazia, Millennium, NextSource, Novartis, Novocure, Orbus, Pfizer, QED, Semus, Servier, and VBI Vaccines, consulting fees from Bayer, Bioclinica as a blinded reader for a BMS-sponsored trial, Karyopharm, Novocure, Orbus, Sapience, and Vivacitas, and travel/in-kind support from AbbVie, Karyopharm, Novartis, Pfizer, QED, and VBI Vaccines.